Contact Us
Subscribe
e-Edition

Dashboard
Logout

- My Account
- Dashboard
- Profile
- Saved items
- Logout

68° Partly Cloudy

Site search

Home
News
- Local News
Sports
Obituaries
e-Edition
Classifieds
Explore the Sheyenne
Archives
Best of 2026

Recent Quotes

View Full List

My Watchlist

Match Group, Inc. - Common Stock

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Articles published by CEL-SCI Corporation

< Previous 1 2 3 4 Next >

CEL-SCI to Pursue Canada’s Conditional Approval Pathway for Multikine in the Treatment of Head & Neck Cancer

April 19, 2023

From CEL-SCI Corporation

Via Business Wire

Tickers CVM

CEL-SCI’s Multikine Phase 3 Cancer Study Shows 43% Survival Extension

March 08, 2023

From CEL-SCI Corporation

Via Business Wire

Tickers CVM

CEL-SCI to Present New Phase 3 Data at European Congress on Head & Neck Oncology

March 03, 2023

From CEL-SCI Corporation

Via Business Wire

Tickers CVM

CEL-SCI Corporation Reports First Quarter Fiscal 2023 Financial Results

February 15, 2023

From CEL-SCI Corporation

Via Business Wire

Tickers CVM

CEL-SCI Reports Fiscal 2022 Financial Results and Clinical & Corporate Developments

December 28, 2022

From CEL-SCI Corporation

Via Business Wire

Tickers CVM

CEL-SCI Corporation Issues Letter to Shareholders

November 22, 2022

From CEL-SCI Corporation

Via Business Wire

Tickers CVM

CEL-SCI’S Multikine Reduced 5-year Death Rate From 54% to 22% in Phase 3 Study Patients Who Were Early Tumor Responders Prior to Any Standard of Care Treatment

October 17, 2022

From CEL-SCI Corporation

Via Business Wire

Tickers CVM

CEL-SCI’S Phase 3 Data Presented at ESMO 2022: Neoadjuvant Multikine Achieved Groundbreaking Tumor Response & Extended Overall Survival in Locally Advanced Head and Neck Cancer

September 12, 2022

From CEL-SCI Corporation

Via Business Wire

Tickers CVM

CEL-SCI Corporation Issues Letter to Shareholders

September 07, 2022

From CEL-SCI Corporation

Via Business Wire

Tickers CVM

CEL-SCI Corporation Announces Phase 3 Multikine® Head and Neck Cancer Results Posted on Clinicaltrials.gov

August 19, 2022

From CEL-SCI Corporation

Via Business Wire

Tickers CVM

CEL-SCI Corporation Reports Third Quarter Fiscal 2022 Financial Results

August 15, 2022

From CEL-SCI Corporation

Via Business Wire

Tickers CVM

CEL-SCI Appoints Dr. Gail Naughton to Its Board of Directors

August 08, 2022

From CEL-SCI Corporation

Via Business Wire

Tickers CVM

CEL-SCI Corporation Announces Reddit AMA with Geert Kersten

July 14, 2022

From CEL-SCI Corporation

Via Business Wire

Tickers CVM

CEL-SCI Corporation to Present at LD Micro Invitational

June 08, 2022

From CEL-SCI Corporation

Via Business Wire

Tickers CVM

CEL-SCI Presents Phase 3 Multikine Head & Neck Cancer Data at ASCO

June 07, 2022

From CEL-SCI Corporation

Via Business Wire

Tickers CVM

CEL-SCI Announces Publication of ASCO 2022 Abstracts

May 27, 2022

From CEL-SCI Corporation

Via Business Wire

Tickers CVM

CEL-SCI Corporation Reports Second Quarter Fiscal 2022 Financial Results

May 16, 2022

From CEL-SCI Corporation

Via Business Wire

Tickers CVM

CEL-SCI Announces Acceptance of Abstracts to ASCO 2022

April 22, 2022

From CEL-SCI Corporation

Via Business Wire

Tickers CVM

CEL-SCI Corporation Reports First Quarter Fiscal 2022 Financial Results

February 14, 2022

From CEL-SCI Corporation

Via Business Wire

Tickers CVM

CEL-SCI Reports Fiscal 2021 Financial Results and Clinical & Corporate Developments

December 22, 2021

From CEL-SCI Corporation

Via Business Wire

Tickers CVM

CEL-SCI Corporation Completes Commercial-Scale Buildout of Multikine Manufacturing Facility

October 22, 2021

From CEL-SCI Corporation

Via Business Wire

Tickers CVM

CEL-SCI Corporation Reports Third Quarter Fiscal 2021 Financial Results

August 16, 2021

From CEL-SCI Corporation

Via Business Wire

Tickers CVM

CEL-SCI Corporation Issues Letter to Shareholders

July 07, 2021

From CEL-SCI Corporation

Via Business Wire

Tickers CVM

Discussion of Results of CEL-SCI’s Phase 3 Trial Is Now Available

July 02, 2021

From CEL-SCI Corporation

Via Business Wire

Tickers CVM

CEL-SCI to Conduct Investor Call Regarding Phase 3 Results Following Annual Shareholder Meeting on July 1, 2021

June 30, 2021

From CEL-SCI Corporation

Via Business Wire

Tickers CVM

CEL-SCI’s Multikine® Immunotherapy Produces Significant 14.1% 5-Year Survival Benefit (62.7% Vs 48.6%) in the Group Receiving Surgery Plus Radiotherapy in a Landmark Head and Neck Cancer Phase 3 Study

June 28, 2021

From CEL-SCI Corporation

Via Business Wire

Tickers CVM

CEL-SCI Corporation Invites Participants to Pre-Submit Questions for Annual Shareholder Meeting

June 25, 2021

From CEL-SCI Corporation

Via Business Wire

Tickers CVM

CEL-SCI Announces the Closing of $31.7 Million Bought Deal Offering

June 11, 2021

From CEL-SCI Corporation

Via Business Wire

Tickers CVM

CEL-SCI Increases Previously Announced Bought Deal to $31.7 Million

June 08, 2021

From CEL-SCI Corporation

Via Business Wire

Tickers CVM

CEL-SCI Announces Bought Deal Offering

June 08, 2021

From CEL-SCI Corporation

Via Business Wire

Tickers CVM

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sections

Home
News
Entertainment
Local Events
Sports
Obituaries
Multimedia
Online Features

Services

Subscription Services
Submission Forms
Classifieds
Place an Ad
Promote Your Event
Email Alerts
Search
Weather

times-online.com
146 Third St. N.E.
Valley City, ND 58072
Phone: 701-845-0463
Email: editor@times-online.com

Facebook
Twitter

Browser Compatibility

Your browser is out of date and potentially vulnerable to security risks.
We recommend switching to one of the following browsers:

Microsoft Edge Google Chrome Firefox

Articles published by CEL-SCI Corporation

Sections

Services

Follow Us